The Filing Desk

Ocugen

OCGN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

OCGN · Last close · November 19, 2026
$0.73
Value Ocugen yourself

Ocugen's revenue rose 8.8% to $4 million in fiscal 2025. Its operating margin was −1,425.7%, down from −1,350.4% a year earlier. Free cash flow was −$57 million.

OCUGEN, INC. Latest fiscal year ended December 31, 2025 10-K filed March 4, 2026 · 0001628280-26-014435 Updated
Revenue
$4M
8.8%
Operating margin
−1,425.7%
75.3 pts
Net income
−$68M
 
Free cash flow
−$57M
 
Return on equity
−776.9%
622.9 pts
Market cap
$249M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Ocugen does

Ocugen is a clinical-stage biotechnology company working on gene therapies for eye diseases that can cause blindness. It has no approved products, so it has no product sales. It describes its main approach as a modifier gene therapy platform, built on nuclear hormone receptors, that it hopes can treat diseases without depending on which gene mutation a patient has.

Its lead candidate, OCU400, is for retinitis pigmentosa, an inherited disease of the retina. It has finished enrolling its Phase 3 trial and says it plans to begin a rolling submission of a biologics license application (BLA) to the FDA in the third quarter of 2026. A second candidate, OCU410ST, is in a Phase 2/3 pivotal confirmatory trial for Stargardt disease, and the company plans a BLA for it in the first half of 2027. A third, OCU410, is in a Phase 1/2 trial for geographic atrophy, an advanced form of dry age-related macular degeneration. It also has an early-stage protein drug, OCU200, for diabetic eye disease and wet age-related macular degeneration.

Without product revenue, it pays for its work by raising money. As of February 24, 2026, it had 116 employees, 79 of them in the United States, 34 in India and three in Canada.

Its biggest risks, as it describes them

  • It has lost money since it began and expects to need substantial new funding, which may not be available.
  • It has never sold a medicine, and its candidates may fail in trials or be denied regulatory approval.
  • Its gene therapies use a new technology with an uncertain regulatory path.
  • Clinical trials may be delayed, and early results may not predict later ones.
  • Making biologic medicines is complex and carries its own risks.
From Ocugen's annual report on Form 10-K, filed March 4, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Ocugen lost money in fiscal 2025: a net loss of $68 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments9591405919
Debt incl. finance leases2232929
Net debt (negative means net cash)−93−89−37−3010
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.1x1.0x—
Interest coverage−734.5x——−79.6x−12.1x
Current ratio14.7x3.5x2.5x2.9x1.1x
Quick ratio14.7x3.5x2.5x2.9x1.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ocugen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $25,830 of Ocugen shares on the open market, and 1 insider sold $589,110, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 9, 2026Shankar MusunuriChief Executive Officer, DirectorSold plan525,991$1.12$589,110Form 4
Jun 15, 2026Treerita Essalima Johnson-GreeneChief Financial OfficerBought21,000$1.23$25,830Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 8——
Rule of 40−1,059.0%−1,155.6%−1,286.2%
Altman Z''−16.87−14.14−40.32
Accruals ratio−1.2%−16.2%−17.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailPassFail
Share count didn't riseFail——
Gross margin rose———
Revenue rose relative to assetsPassPassFail
F-score3 of 8——
Companies that report no gross profit are scored on the other eight.

Compare

Put Ocugen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
OcugenFY258.8%−1,425.7%−1,295.0%———
Prime MedicineFY2555.3%−4,498.1%−3,607.4%———Compare
CG OncologyFY25254.7%−4,722.1%−3,279.2%——2Compare
CerenomeFY25−10.5%−293.5%−399.8%———Compare
CRISPR TherapeuticsFY25−90.6%−18,933.7%−9,855.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0000002644
Revenue growth—————−100.0%—142.6%−32.8%8.8%
Gross profit——————————
Research and development221610863556403240
Operating income−30−25−16−14−21−58−89−66−55−63
Net income−16−26−18−20−22−58−87−63−54−68
Diluted EPS (US$)−2.18−0.99−0.79−1.46−0.31−0.30−0.40−0.26——
Diluted shares (millions)14233714112195215244——
Cash flow
Cash from operations−26−23−12−17−15−48−60−62−42−57
Capital expenditure00000141030
Free cash flow−26−23−12−17−15−49−65−73−46−57
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation22211710978
Balance sheet at fiscal year end
Cash and short-term investments328—7249591405919
Debt incl. finance leases——8122232929
Total assets361121727106109648244
Total liabilities222215661035245356
Shareholders' equity144−13112291744130−12
Margins and ratios
Gross margin——————————
Operating margin————−49,500.0%—−3,580.0%−1,085.7%−1,350.4%−1,425.7%
Net margin————−50,748.8%—−3,488.9%−1,045.0%−1,333.0%−1,537.4%
Free cash flow margin————−34,920.9%—−2,593.9%−1,201.6%−1,122.7%−1,295.0%
Rule of 40 (growth + FCF margin)———————−1,059.0%−1,155.6%−1,286.2%
Return on capital————−750.5%—————
Return on equity−77.6%−293.5%——−134.0%−103.5%−105.1%−110.1%−154.0%−776.9%
Return on assets−44.5%−112.1%−270.1%−210.2%−98.8%−87.7%−81.0%−72.8%−73.5%−107.7%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ocugen's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ocugen.